DUBLIN – (BUSINESS WIRE) – May 20, 2021 –
the “Chinese Ibrutinib Market Investigation Report 2021-2025” the report was added to ResearchAndMarkets.comoffer.
As of 2020, Pharmacyclics Inc is the only manufacturer in the Chinese market of ibrutinib.
Ibrutinib is a BTK inhibitor, primarily used to treat B cell carcinomas, such as mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström’s macroglobulinemia.
Ibrutinib was first developed by Johnson & Johnson and Pharmacyclics Inc. Pharmacyclics Inc was acquired by AbbVie in 2015. Their Ibrutinib, IMBRUVICA, was launched in China in 2017.
According to this market research, after ibrutinib entered the Chinese market, the value of ibrutinib sales in China increased from CNY 48,600 in 2017 to CNY 345.5 million in 2020. In 2020, the growth rate was 38.2%, which slowed down due to the COVID-19 outbreak. The CAGR of Ibrutinib sales value in China is 1823% from 2017 to 2020.
The analyst analyzes that as the epidemic situation has improved and hospitals resume operations, sales of Ibrutinib will experience recovery growth from 2021 to 2025. In addition, sales will also increase in due to price reduction and market expansion. Currently, Ibrutinib has three approved indications.
In 2020, the last approved indication was included in the national health insurance catalog, while the other two were included in the catalog in 2018. As all indications can benefit from insurance reimbursement, the rate d use of ibrutinib will increase in patients. .
Additionally, with the emergence of other BTK inhibitor drugs, the price of ibrutinib may continue to decline, leading to increased sales. In contrast, China approves fewer indications for ibrutinib than other countries. Therefore, the number of approved indications has the potential to increase, which means that the market will continue to expand in the future.
- The impact of COVID-19 on the Chinese ibrutinib market
- Chinese Ibrutinib Sales Value and Volume 2016-2020
- Competitive landscape of the Chinese ibrutinib market
- Price of ibrutinib in China
- China Ibrutinib Price by Regions and Manufacturers
- Analysis of factors affecting the development of the Chinese ibrutinib market
- China ibrutinib market outlook from 2021 to 2025
Main topics covered:
1 Relevant concepts of ibrutinib
1.1 Indications for ibrutinib
1.2 Development of ibrutinib in China
1.3 Government approval of ibrutinib in China
1.4 The impact of COVID-19 on sales of Ibrutinib in China
2 Ibrutinib sales in China, 2017-2020
2.1 Ibrutinib sale value
2.2 Ibrutinib sales volume
2.3 China Ibrutinib Sales by Dosage Form, 2017-2020
2.3.2 Analysis of other dosage forms
3 China Major Manufacturers Analysis of Ibrutinib, 2017-2020
3.1 Major Manufacturers of Ibrutinib Market Share Analysis
3.1.1 Market Share Based on Sales Value Survey
3.1.2 Market Share Based on Sales Volume Survey
3.2 Pharmacyclics Inc
3.2.1 Company profile
3.2.2 Sales of IMBRUVICA (Ibrutinib by Pharmacyclics Inc.) in China
4 Ibrutinib Price for Different Manufacturers in China, 2020-2021
4.1 Pharmacyclics Inc (IMBRUVICA)
5 China Ibrutinib Drug Market Outlook, 2021-2025
5.1 Factors influencing the development of the Chinese ibrutinib market
5.1.1 The impact of COVID-19 on the Chinese ibrutinib market
5.1.2 Market Drivers and Opportunities
5.1.3 Market threats and challenges
5.2 Market Size Forecast
5.3 Market Trend Forecast
- Johnson & johnson
- Pharmacyclics Inc
For more information on this report, visit https://www.researchandmarkets.com/r/x036vs
View source version on businesswire.com:https://www.businesswire.com/news/home/20210520005596/en/
Laura Wood, Senior Press Officer
For EST office hours, dial 1-917-300-0470
For USA / CAN call toll free 1-800-526-8630
For GMT office hours, call + 353-1-416-8900
KEYWORD: CHINA ASIA PACIFIC
INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH
SOURCE: Research and markets
Copyright Business Wire 2021.
PUB: 05/20/2021 8:02 a.m. / DISC: 05/20/2021 8:03 a.m.
Copyright Business Wire 2021.